The pacemaker under complaint has not been returned.Therefore, the analysis is based on the available device data as well as on the complaint description.The manufacturing process for this device was re-investigated and all production steps were performed accordingly.There was no sign of any inconsistency during the manufacturing process.The described device behavior in regard to left ventricular capture control is as expected and in accordance to specification.In case the algorithm is not able to find a stable threshold the maximum pulse amplitude is set to the programmed start value plus a safety margin of 1.2v which results in 3.6v pulse amplitude in this case which is the specified behavior.There was no indication of a device malfunction.A possible root cause for the described clinical observation could be a lead problem of the implanted left ventricular lead.There are no further information about this lead available as it is a competitor product.
|